구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | (F-18)-DCFPyL (F-18, (F-18)-DCFPyL) Progenics Pharmaceuticals, Inc.·Metastatic Renal Cell Carcinoma 153 trials |
|---|---|
Overview Program | (F-18)-DCFPyL |
Overview Company | Progenics Pharmaceuticals, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Renal Cell Carcinoma |
Overview Indication | Metastatic Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target proteins, pathway |
MoA Biomarker | PD-L1) expression |
PK/PD Species | NHP, Rat |
PK/PD Animal (cat.) | Rat, NHP, In vitro |
PK/PD Experiment | PD |
Toxicology Species | NHP, Rat |
Toxicology Animal (cat.) | Rat, NHP, In vitro |
Toxicology Major finding | Biodistribution, radiodosimetry and pharmacokinetics of [ 18 F]GSK1482160 for cerebral P2X7 receptor in living subjects.. BACKGROUND: Increasing evidence of the role of neuroinflammation in pathophysiology has highlighted the importance of P2X7 receptor (P2X7R)-targeted neurodegeneration diseases. The safety, biodistribution, pharmacokinetics and dosimetry of a promising F-18-labeled PET tracer [1… |
Clinical Safety signal | Biodistribution, radiodosimetry and pharmacokinetics of [ 18 F]GSK1482160 for cerebral P2X7 receptor in living subjects.. BACKGROUND: Increasing evidence of the role of neuroinflammation in pathophysiology has highlighted the importance of P2X7 receptor (P2X7R)-targeted neurodegeneration diseases. The safety, biodistribution, pharmacokinetics and dosimetry of a promising F-18-labeled PET tracer [1… |
Clinical Selected reported efficacy | ORR 100% |
Clinical Reported ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT02680041 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02680041 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | (F-18)-DCFPyL (F-18, (F-18)-DCFPyL) Progenics Pharmaceuticals, Inc.·Metastatic Renal Cell Carcinoma 153 trials |
|---|---|
Overview Program | (F-18)-DCFPyL |
Overview Company | Progenics Pharmaceuticals, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Renal Cell Carcinoma |
Overview Indication | Metastatic Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target proteins, pathway |
MoA Biomarker | PD-L1) expression |
PK/PD Species | NHP, Rat |
PK/PD Animal (cat.) | Rat, NHP, In vitro |
PK/PD Experiment | PD |
Toxicology Species | NHP, Rat |
Toxicology Animal (cat.) | Rat, NHP, In vitro |
Toxicology Major finding | Biodistribution, radiodosimetry and pharmacokinetics of [ 18 F]GSK1482160 for cerebral P2X7 receptor in living subjects.. BACKGROUND: Increasing evidence of the role of neuroinflammation in pathophysiology has highlighted the importance of P2X7 receptor (P2X7R)-targeted neurodegeneration diseases. The safety, biodistribution, pharmacokinetics and dosimetry of a promising F-18-labeled PET tracer [1… |
Clinical Safety signal | Biodistribution, radiodosimetry and pharmacokinetics of [ 18 F]GSK1482160 for cerebral P2X7 receptor in living subjects.. BACKGROUND: Increasing evidence of the role of neuroinflammation in pathophysiology has highlighted the importance of P2X7 receptor (P2X7R)-targeted neurodegeneration diseases. The safety, biodistribution, pharmacokinetics and dosimetry of a promising F-18-labeled PET tracer [1… |
Clinical Selected reported efficacy | ORR 100% |
Clinical Reported ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT02680041 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02680041 |
추천 비교
추천 비교